Day: April 13, 2023

Omnichannel-first companies are seeing a growth multiplier effect 2x that of their peers

NEW YORK and LONDON, April 13, 2023 (GLOBE NEWSWIRE) — McKinsey & Company’s latest Global B2B Pulse reveals that market share winners are going all in on omnichannel, even in uncertain times.

In particular, companies that reported a 10+ percent increase in market share last year deployed five specific omnichannel strategies in concert:

• Hybrid sales teams and capabilities
• Highly personalized marketing
• Advanced sales technology usage
• Third-party marketplaces strategies
• Ecommerce excellence in owned platforms

Each strategy is valuable on its own, but they are most powerful when combined. Companies who invested in all five were twice as likely to gain market share than companies who adopted only one.

The Global B2B Pulse research analyzed responses from nearly 3,800 sales and marketing leaders across 13 countries. Since 2016, the B2B Pulse has gathered insights from almost 25,000 decision makers globally. This year’s Pulse reveals that omnichannel is now a must-have requirement in B2B marketing and sales.

Additional insights and trends include:

Personalization shifts up a gear
77 percent of companies using direct 1:1 personalization saw an increase in market share. But companies showing the strongest market share growth – more than 10 percent a year – were overwhelmingly investing in sophisticated tactics that go beyond account-based marketing, like hyper-personalization. This form of personalization is growing most in Brazil, India, and the US, and driving market share growth particularly in the global energy and materials (GEM), finance, banking, and insurance, and telecommunications, media, and technology (TMT) sectors.

Market share winners are also investing in new sales tools that aid hyper-personalization. For example, 64 percent of share winners are using bots. Tools like these are increasingly used to accelerate and sharpen personalization for every customer at each stage of the buying journey. Stronger personalization helps ensure customers are presented with the right message, the right call to action, and the right products and solutions, all at the right time.

Appetite for high-value e-commerce transactions on the rise
The Pulse research also showed that, like last year, ~70 percent of decision makers are prepared to spend up to $500,000 in a single e-commerce transaction. Meanwhile, the number of buyers willing to spend up to $10 million in a single e-commerce transaction rose by 83 percent. This trend is particularly prominent in China, India, and the US – and especially within the global energy and materials (GEM); telecommunications, media, and technology (TMT); and advanced industries sectors.

B2B marketplaces present clear growth opportunity 
In a significant shift from legacy methods, 35 percent of B2B decision-makers now rate e-commerce as their most effective sales channel. The companies winning the most market share enable their customers to buy online through multiple channels. For instance, 48 percent of growing organizations sell via industry-specific marketplaces, while only 13 percent of organizations losing market share do. E-commerce comes ahead of in-person sales (26 percent), videoconferencing (12 percent), email (10 percent), and telephone (8 percent). The best results demand investment in experimentation and optimization over time. Strong execution requires consistent optimization, experimentation, and training for internal teams.

More than half of winning companies use hybrid sales teams
Hybrid sales models, which involve sales staff meeting with customers both in-person and remotely, were used by 57 percent of companies that are growing their market share. For companies losing market share, that figure is 40 percent. Today’s B2B customers need sales leaders to be available not only in-person, but also through remote sales meetings, virtual demonstrations, and digital relationship management.

This increased use of larger hybrid teams is particularly linked with market share growth in the telecommunications, media, and technology, global finance, banking and insurance, as well as travel, transportation, and logistics sectors.

Jennifer Stanley, Partner, McKinsey & Company:
“These trends we are seeing continue to shake things up for companies. And the signals are clear – customers know exactly what, where, how, and when they want things. What’s even more clear? Companies that adapt and respond to those needs and provide value are being rewarded in multiple ways – from higher retention rates, higher sales, and higher market share.”

Candace Lun Plotkin, Partner, McKinsey & Company:
“It’s a defining moment for sales and marketing leaders. Companies that are defying the odds and going all in on critical investments and growth levers are realizing market share gains at a faster clip. What this means for those who are looking to emerge stronger, is that growth – even in this difficult climate – is attainable. It comes down to charting that path and taking decisive action.”

For more insights, see the full report.

About the survey
McKinsey’s Global B2B Pulse has been published annually since 2016 and has now gathered insights from over 25,000 decision-makers. The most recent survey of 3,800 leaders across 13 countries (Brazil, Chile, China, France, Germany, India, Italy, Japan, South Korea, Spain, the United Kingdom, and United States) was conducted in December 2022.

About Growth, Marketing & Sales, McKinsey & Company 
The mission of the McKinsey Growth, Marketing & Sales Practice is to help leaders of both consumer and business-to-business organizations drive sustainable and inclusive growth, through meaningful transformations and marketing-driven profit. The practice helps its clients set their strategic direction, develop their marketing and sales capabilities, and connect their organization to realize the full potential of today’s omnichannel opportunities. Clients benefit from McKinsey’s experience in core areas of marketing such as branding, customer insights, marketing ROI, digital marketing, CLM pricing, and sales and channel management.

For more information, please contact:

US media contact: Alyssa Kehoe, Digennaro Communications, McKinsey-DiGennaro@digennaro-usa.com, +1 917 518 8422

UK media contact: Ruth Jones/Becca Ross, 3THINKRS, mckinsey@3thinkrs.com, +44 0208 0872843

GlobeNewswire Distribution ID 8807680

KUALA LUMPUR, Malaysia, April 13, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) announced that its ordinary shares have commenced trading on The Nasdaq Capital Market today under the ticker symbol “VCIG.”

On April 13, 2023, the Company priced its firm commitment underwritten public offering (the “Offering”) of 1,280,000 shares of ordinary shares at a public offering price of $4.00 per share. The gross proceeds to the Company from the Offering are expected to be $5,120,000 (not including any exercise by the underwriter of its over-allotment option) before deducting underwriting discounts, commissions and other Offering expenses.

Boustead Securities, LLC and Sutter Securities, Inc. acted as the underwriters for the firm commitment Offering.

A registration statement on Form F-1, as amended (File No. 333-268109), filed by the Company with the Securities and Exchange Commission (the “SEC”), was declared effective on March 30, 2023. The Offering has been made only by means of a prospectus. A copy of the final prospectus related to the Offering, which was filed with the SEC, may be obtained, when available, from Boustead Securities, LLC, via email: offerings@boustead1828.com, or by calling +1 (949) 502-4408, or by standard mail at Boustead Securities, LLC, Attn: Equity Capital Markets, 6 Venture, Suite 395, Irvine, CA 92618, USA. In addition, a copy of the final prospectus, when available, relating to the Offering may be obtained via the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About VCI Global Limited

VCI Global is a multi-disciplinary consulting group with key advisory practices in the areas of business and technology. The Company provides business and boardroom strategy services, investor relation services, and technology consultancy services. Its clients range from small-medium enterprises and government-linked agencies to publicly traded companies across a broad array of industries. VCI Global operates solely in Malaysia, with clients predominantly from Malaysia, but also serves some clients from China, Singapore, and the US.

For more information on the Company, please log on to https://v-capital.co/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of Coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

Issued by Imej Jiwa Communications Sdn Bhd and ICR Inc. on behalf of VCI Global Limited
For media queries, please contact:

Imej Jiwa Communications Sdn Bhd
Chris Chuah
Email: chris@imejjiwa.com

ICR Inc.
Investor Relations
Michael Bowen
Vciglobal.ir@icrinc.com

Public Relations
Brad Burgess
Vciglobal.pr@icrinc.com

Boustead Securities, LLC
Underwriter
Dan McClory, Head of Equity Capital Markets
dan@boustead1828.com

GlobeNewswire Distribution ID 8807578

KUALA LUMPUR, Malaysia, April 13, 2023 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global”, or the “Company”) today announced the pricing of its initial public offering of 1,280,000 shares of its ordinary shares at a price to the public of $4.00 per share for a total of $5,120,000 of gross proceeds to the Company (the “Offering”), before deducting underwriting discounts, commissions and other Offering expenses. In addition, VCI Global has granted the underwriters a 45-day option to purchase up to an additional 192,000 of its ordinary shares at the public offering price of $4.00 per share, less the underwriting discounts and commissions, to cover over-allotments, if any.

The shares are expected to begin trading on The Nasdaq Capital Market today, April 13, 2023, under the ticker symbol “VCIG.” The Offering is expected to close on April 17, 2023 subject to the satisfaction of customary closing conditions.

Boustead Securities, LLC and Sutter Securities, Inc. are acting as the underwriters for the Offering.

A registration statement on Form F-1, as amended (File No. 333-268109) relating to these securities was filed with the Securities and Exchange Commission (“SEC”) and was declared effective on March 30, 2023. The Offering is being made only by means of a prospectus. A copy of the final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. A copy of the final prospectus relating to the Offering may be obtained, when available from Boustead Securities, LLC by way of emailing requests to offerings@boustead1828.com; or by calling 1-949-502-4408; or by request by standard mail to Boustead Securities, LLC, Attention: Equity Capital Markets, 6 Venture, Suite 395, Irvine, California 92618, USA.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About VCI Global Limited

VCI Global is a multi-disciplinary consulting group with key advisory practices in the areas of business and technology. The Company provides business and boardroom strategy services, investor relation services, and technology consultancy services. Its clients range from small-medium enterprises and government-linked agencies to publicly traded companies across a broad array of industries. VCI Global operates solely in Malaysia, with clients predominantly from Malaysia, but also serves some clients from China, Singapore, and the US.

For more information on the Company, please log on to https://v-capital.co/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including without limitation, the Company’s ability to achieve profitable operations, customer acceptance of new products, the effects of the spread of Coronavirus (COVID-19) and future measures taken by authorities in the countries wherein the Company has supply chain partners, the demand for the Company’s products and the Company’s customers’ economic condition, the impact of competitive products and pricing, successfully managing and, general economic conditions and other risk factors detailed in the Company’s filings with the United States Securities and Exchange Commission. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update the forward-looking statements in this release, except in accordance with applicable law.

CONTACT INFORMATION:

Issued by Imej Jiwa Communications Sdn Bhd and ICR Inc. on behalf of VCI Global Limited
For media queries, please contact:

Imej Jiwa Communications Sdn Bhd
Chris Chuah
Email: chris@imejjiwa.com

ICR Inc.
Investor Relations
Michael Bowen
Vciglobal.ir@icrinc.com

Public Relations
Brad Burgess
Vciglobal.pr@icrinc.com

Boustead Securities, LLC
Underwriter
Dan McClory, Head of Equity Capital Markets
dan@boustead1828.com

GlobeNewswire Distribution ID 8807457

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

• Funds will support the Phase I/II clinical development of Alentis’ two first-in-class anti-Claudin-1 (CLDN1) antibodies for organ fibrosis and CLDN1 positive tumors, and CLDN1 platform development
• After its investment 2 years ago, Jeito Capital amplifies its partnership with Alentis Therapeutics, the leading player in CLDN1, in line with its strategy to grow companies and build potential market leaders to bring much needed treatments to benefit patients

Paris, France, April 13^th 2023 – Jeito Capital (“Jeito”), the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced today that it has led a $105 million (€96 million) Series C financing in Alentis Therapeutics (“Alentis” or the “Company”), a clinical-stage biotech spun out of INSERM, based in Basel (Switzerland) with R&D in Strasbourg (France), that is developing breakthrough treatments for organ fibrosis and CLDN1 positive tumors. CLDN1, as part of the claudin family of transmembrane proteins, is a previously unexploited target that plays a key role in the physio-pathology of a broad range of solid tumors with immune evasive properties and fibrotic diseases across multiple organs.

The financing was led by Jeito together with Novo Holdings A/S and RA Capital Management with participation from existing investors including BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund and Schroders Capital. Proceeds will be used to support the Phase II program of Alentis’ lead investigational products, ALE.F02, currently in development for the treatment of advanced kidney, lung and liver fibrosis, and the Phase I program of its lead oncology asset, ALE.C04, the first potential treatment to target CLDN1 positive (CLDN1+) tumors. Funds will also be used to develop the Company’s platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies. The Claudin space in oncology has recently seen the success of CLDN-18.2 in gastric cancers. CLDN-1 has the advantage of a much broader expression profile, highlighting Alentis’ growth potential and significant commercial potential.

Jeito became a key investor in Alentis as part of a $67 million Series B financing in June 2021. Since then, Alentis has made significant progress. The Company’s Phase I multiple ascending dose study for ALE.F02 is expected to reach completion imminently. Alentis has also clearly defined the CLDN1+ cancer patient population, including T-cell excluded cancers, as the target for developing its ALE.C04 oncology treatment. The Company has established a platform to engineer CLDN1 ADCs (antibody drug conjugates) and bi-specific antibodies and has expanded its team in France, Switzerland and the US.

Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented “Claudin-1 has enormous potential in multiple areas of fibrosis and across a broad range of cancers and, with Jeito’s support, Alentis has made significant progress over the past two years in identifying target populations while developing programs and advancing the platform. We are committed to continuing our partnership with the outstanding Alentis team as they are the leading player in the CLDN1 space and are well positioned to generate meaningful clinical data.“

Dr. Roberto Iacone, CEO at Alentis Therapeutics, said: “We are absolutely delighted with this support from our investors. There are huge unmet needs in organ fibrosis and cancer, and this funding enables us to continue with the important work we’re doing in the CLDN1 space and generate clinical data from both our programs. We can now aggressively develop CLDN1 biology in oncology and continue with the recruitment of our organ fibrosis trials while advancing our ADC and bi-specific antibodies.”

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

@Jeito_lifeLinkedInFor more information, please visit www.jeito.life, or follow @Jeito_life on Twitter or LinkedIn.
About Alentis Therapeutics

Alentis Therapeutics, the CLDN1 company, is a clinical-stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis. Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors with immune evasive properties and fibrotic disease across multiple organs.

Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with an R&D subsidiary in Strasbourg, France and clinical operations in the US.

Visit https://alentis.ch

For further information please contact:

Jeito Capital
Rafaèle Tordjman, Founder & CEO
Assia Mouhout, EA
Tel : +33 6 76 49 37 94

Consilium Strategic Communications Mary-Jane Elliott / Davide Salvi / Kris Lam
Jeito@consilium-comms.com
Tel: +44 (0) 20 3709 5700

Marion Bougeard
marion@achto-conseil.fr
Tel : +33 6 76 73 57 31

GlobeNewswire Distribution ID 1000803581